Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb

Results impacted by diabetes divestiture

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb

2Q Revenues: $3.9 billion (-4%)

2Q Earnings: $334.0 million (-37%)

YTD Revenues: $7.7 billion (-2%)

YTD Earnings: $1.3 billion (+10%)

Comments: U.S. revenues decreased 7% to $1.9 billion in the quarter and International revenues were down 1% to $2.0 billion. Reyataz sales were down 16% to $362 million. The Sustiva Franchise was down 12% to $361 million. Eliquis sales grew by $159 million, Yervoy sales were up 38% to $321 million, Sprycel sales grew 18% to $368 million, and Orencia sales were $402 million, up 14%. R&D expenses were up 49% to $1.4 billion in the quarter and included impairment and acquisition-related charges of $458 million. Results in the quarter were impacted by the divestiture of the diabetes alliance.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters